Layout Table~~~~2273~2273~~

Emerging Markets for Microfluidic Applications~
Published by Yole Développement, May 2007

Microfluidics is becoming a key technology integrated in most of Life Science companies’ development roadmap. Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.~Published by Yole Développement, May 2007

Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.

The microfluidics market for research applications will steadily grow in the 5 coming years, but the double digit growth will come from the diagnostic market. Indeed microfluidics has a strong competitive advantage in this market enabling analysis automation and decentralisation, but also in facilitating the molecular diagnostic emergence and success.

Microfluidics components for diagnostic are expected to reach €1b market value in 2011 with a Total Accessible Market of about 5b€.

If microfluidics proof of concept is validated now, no real standard has been defined yet. Dedicated to research applications, microfluidics products are rather produced in low volume. The microfluidics penetration in the diagnostic market will require the technology validation from a manufacturability point of view. Only the technologies fitting with the diagnostic market cost and regulation pressure will success.

Such standardisation will lead to a structuration of the industrial food chain. New players are entering the field. Some microfluidics companies adapt their business model to the market evolution. Mergers and acquisitions are also increasing.

Most of diagnostic companies have positioned microfluidics in their development roadmap as a key technology to support their growth strategy.

Indeed microfluidics is clearly identified as an enabling technology to support the development of the point of care and the molecular biology markets.

All ingredients are gathered for success:

1 - Microfluidics is overcoming the proof of concept milestones. Some companies are today positioned in microfluidics industrialisation

2 - Microfluidics provides the expected technical solutions required in the diagnostic market evolution

3 - Innovative high tech companies are entering the diagnostic field. They will participate to the market dynamism in facilitating convergence of technologies like microfluidics and biomarkers.~Emerging Markets for Microfluidic Applications (Single User License)|1052|Emerging Markets for Microfluidic Applications (Corporate License)|1168|Emerging Markets for Microfluidic Applications (Corporate Multi Site License)|1169|~2273~3203~~

Point of Care Diagnostics Market in the US:~
Published by BioPerspectives, August 2006

This new report is the ideal tool for planning for success. The comprehensive analysis of the US market is based on (1) a proprietary comprehensive database of tests, (2) discussions with clinicians, (3) detailed assessments of current and emerging technologies, and (4) CDC, FDA, and professional organizational guidelines and publications. Twenty-one figures, 32 tables, and 57 company profiles present the information in a clear and accessible manner. “Point of Care Diagnostics Market in the US: Opportunities and Challenges” is the go-to tool for those wishing to enter and those wishing to stay current in this dynamic market.~Published by BioPerspectives, August 2006

This new report is the ideal tool for planning for success. The comprehensive analysis of the US market is based on (1) a proprietary comprehensive database of tests, (2) discussions with clinicians, (3) detailed assessments of current and emerging technologies, and (4) CDC, FDA, and professional organizational guidelines and publications. Twenty-one figures, 32 tables, and 57 company profiles present the information in a clear and accessible manner. “Point of Care Diagnostics Market in the US: Opportunities and Challenges” is the go-to tool for those wishing to enter and those wishing to stay current in this dynamic market.

Key Highlights of this report:

• Comprehensive proprietary database of point of care diagnostics
• Detailed analyses of performance of tests and technologies
• Detailed pricing information
• Segmentation by therapeutic area and by technology
• Segmentation by instrumentation and tests
• Regulatory hurdles
• Key trends and market drivers
• Opportunities and unmet needs
• Quantitative market model

Table of contents | Sample Pages

~Point of Care Diagnostics Market in the US%3A (Electronic site license)|741|~2273~2579~~

Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D~
Companies Products and WW Market, 2004-2009

Published by Takeda Pacific, July 2005

One of the big ideas that emerged since the completion of the human genome project involves new biomarkers and tests used for tailoring new drugs that match an individual’s genetic makeup. This report is about the market for genomic, metabolomic and protein biomarkers and the related tests. The tests are used as molecular diagnostics and as pharmacogenomic assays to measure drug safety or effectiveness. Takeda Pacific’s report maps out the major areas of the market ecosystem for biomarkers and related tests. This insightful study shows that this market is big business and reached $7.1 billion in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains.

~Companies Products and WW Market, 2004-2009

Published by: Takeda Pacific, July 2005


One of the big ideas that emerged since the completion of the human genome project involves new biomarkers and tests used for tailoring new drugs that match an individual’s genetic makeup. This report is about the market for genomic, metabolomic and protein biomarkers and the related tests. The tests are used as molecular diagnostics and as pharmacogenomic assays to measure drug safety or effectiveness. Takeda Pacific’s report maps out the major areas of the market ecosystem for biomarkers and related tests. This insightful study shows that this market is big business and reached $7.1 billion in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains.

The study projects the 5-year trends for biomarkers, molecular diagnostics and pharmacogenomic tests used by the drug makers. The report charts the developments of more than 50 companies involved in this dynamic industry.

This report discusses new FDA initiatives to accelerate the approvals of emerging diagnostics and new drugs by integrating biomarkers and pharmacogenomic tests drug development from pre-clinical through the end of clinical trial phases. Companies have responded with new products. Roche’s new microarray test, targets certain gene variants, and tests if patients respond well to 30 or more currently marketed drugs. Tailored therapies such as Herceptin, Gleevec, Erbitux, or Irressa are among a new class of marketed products. They work very effectively, but just for a sub-set of individuals that pass special genetic tests designed for each product. These products signal that the era of personalized medicine has begun.

This study is packed with interesting data and includes more than 66 figures and tables. The tables provide data about technologies, companies, product pipelines, partnerships and more. The study also has additional data such as the worldwide incidence and prevalence of major diseases. The report analyzes partnering deals and includes several years of alliance and M&A data.

Twenty-two selected companies are profiled, with details including contact information, business and product overviews, alliances and patent or other financial details. This report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.

Table of Contents~Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D%3A PDF Single User License|52|Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D%3A Site License|53|~2273~2551~~

Medical Biosensor Applications and Market to 2008~
Diabetes Management, Point-of-Care and Related Applications

Published by Takeda Pacific, May 2005

This insightful report discusses the global market for medical biosensors and offers readers interesting information and analysis about key developments driving this market. The study details how medical biosensors are utilized in key medical applications. These applications include home blood glucose monitoring used for diabetes management and clinical biosensor applications including Point-of-Care-Testing devices, IV diagnostics and related applications.~Diabetes Management, Point-of-Care and Related Applications

Published by Takeda Pacific, May 2005

This insightful report discusses the global market for medical biosensors and offers readers interesting information and analysis about key developments driving this market. The study details how medical biosensors are utilized in key medical applications. These applications include home blood glucose monitoring used for diabetes management and clinical biosensor applications including Point-of-Care-Testing devices, IV diagnostics and related applications.

The surge in obesity and the disturbing growth rate of diabetes in the developed world is driving a need for better diabetes management products. Glucose monitors will continue to play an important role in this field. In hospitals, there is a continual need for medical biosensor based devices that are used for real-time Point-of-Care Testing or monitoring of blood gases, other vital signs, and related clinical applications. The acute shortage of available livers, pancreatic cells and kidneys for transplant is driving the need for life sustaining artificial organs. Innovative medical biosensor devices are being developed to work as part of artificial organs such as artificial pancreas, liver or kidney.

Many organizations are working in this field and are seeking new business opportunities. This report discusses the major areas of commercial and R&D activities at academic, private or public centers. This study estimates that the market size for global medical biosensor-based products in 2004 reached about $7.1 billion and is growing at about 9.7% to 2008. Company profiles and tables provide insights about products and trends. The study uses 25 figures and tables to provide the reader with key information

This report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.

Table of Contents~Medical Biosensor Applications and Market to 2008%3A PDF Single User License|68|Medical Biosensor Applications and Market to 2008%3A Site License|69|~2273~1801~~

Molecular Diagnostics~
Published by Select Biosciences, Spring 2005

The molecular diagnostics marketplace offers a growth opportunity given the interest in utilizing molecular tools to precisely target therapeutics.

This report analyzes the technologies and their impact in the molecular diagnostics marketplace. An assessment of all the technologies of value in this market and which market segments are impacted and affected by these technologies.

Furthermore, in this report are presented qualitative and quantitative market analysis of molecular diagnostics. Presented are total industry revenues, growth rates, and the various qualitative drivers that are contributing to the growth of the marketplace.
~Published by Select Biosciences, Spring 2005

The molecular diagnostics marketplace offers a growth opportunity given the interest in utilizing molecular tools to precisely target therapeutics.

This report analyzes the technologies and their impact in the molecular diagnostics marketplace. An assessment of all the technologies of value in this market and which market segments are impacted and affected by these technologies.

Furthermore, in this report are presented qualitative and quantitative market analysis of molecular diagnostics. Presented are total industry revenues, growth rates, and the various qualitative drivers that are contributing to the growth of the marketplace.

Key Highlights of this Report:

• Qualitative and quantitative market analyses, and market forecasts
• Technology assessment and competitive analysis
• All the major technology platforms deployed in molecular diagnostics:
    o Instrumentation
    o Complete Assay Technologies
• Approval processes for molecular diagnostics for US, European Union, and Japan are presented. This is key information for new entrants into this marketplace.
• Segments of the molecular diagnostics marketplace
• Qualitative market drivers
• Quantitative Market Analysis
    o Total market size in terms of industry revenues and growth rate
    o Emerging market segments-and estimated market sizes
    o Growth areas in terms of classes of analytes-biological targets for development of molecular diagnostics

Companies mentioned in the report

A&G Pharmaceutical
Abbott Laboratories
Affymetrix
Amorfix Life Sciences
AstraZeneca
Axis-Shield
Bayer
Biogen Idec
Bristol-Myers Squibb
Cambridge Theranostics
Chiron
Clinical Data
CyGene
DakoCytomation
Digene
DNAPrint Genomics
Epigenomics
EXACT Sciences
Fornix Theranostics
Gemini (Eurona)
Genaissance Pharmaceuticals
Genentech
Genetic Vectors
Gen-Probe
Glaxo Wellcome
HBV Theranostica
Hyseq
IGEN International
ImClone Systems
Innogenetics
Investigen
Itsi-Biosciences
Kingo Diagnostika
Lpath Therapeutics
Merck & CO.
Millennium Predictive Medicine
Myriad Genetics
Neighborhood Connections
NGI
Novartis
Oncogene Science
Organon Teknika
PeptiFarma
PGxHealth
PharmaNetics
Pronto Diagnostics
Provalis
Quidel
Roche
Seapro Theranostics International B.V
Sequenom
The Boston Consulting Group
TheraNostics GmbH
Tibotec-Virco
Ventana Medical Systems
Visible Genetics
Vysis
Wyeth


Table of contents | Sample Pages ~Molecular Diagnostics (single user print version)|757|Molecular Diagnostics (Eletronic site license PDF + One print Copy)|758|~2273~2688~~